Late-stage cell therapy company utilizing proprietary autologous tumor infiltrating lymphocytes (TILs) to attack solid tumors. The company is conducting pivotal stage trial in metastatic melanoma and will define regulatory path in advanced cervical cancer mid-year 2019, with breakthrough therapy designation awarded in May 2019. The company presented data at ASCO 2019:
1. Lifileucel in 66 patients with advanced metastatic melanoma who have progressed on previous therapy and 3.3 median prior therapies: ORR 38% (2 CRs), DCR 80%, and median duration not reached at 8.8 months of follow-up.
2. LN-145 in 27 patients with advanced cervical cancer, with 2.4 mean number of therapies: ORR 44% (3 CRs), DCR 85%, and median duration not reached at 7.4 months of follow-up.
Additional company-sponsored trials: Head & neck cancer, non-small cell lung cancer, and earlier lines in melanoma. The company has IST collaborations in ovarian cancer, bladder cancer, sarcomas, and pancreatic cancer. Iovance plans to initiate study in hematological malignancies: CLL in post-Ibrutinib patients utilizing peripheral blood lymphocytes (PBL).
Phase l or ll
999 Skyway Road
San Carlos, CA 94070
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by